Germline Cancer Testing in Unselected Patients With Neuroendocrine Neoplasms: A Multi-center Prospective Study.

Oluseyi Abidoye¹, Michael Golafshar², Katie Kunz², Cody Eslinger¹, Zaid Elsabbagh³, Samee Zane Alheraki¹, Abdullah Alsulaiman¹, Margaret Klint², Edward Esplin⁴, Robert L Nussbaum⁴, Jason Starr⁵, Daniel Ahn¹, Tanios Bekaii-Saab¹, Thorvardur Halfdanarson⁶, Niloy Jewel Samadder¹, Mohamad Bassam Sonbol¹

¹Mayo Clinic Cancer Center, Arizona.

²Department of Health Services Research, Mayo Clinic, Phoenix, Arizona.

³Department of Medicine, Johns Hopkins University School of Medicine.

⁴Invitae, San Francisco, California.

⁵Mayo Clinic Cancer Center, Florida.

⁶Mayo Clinic Cancer Center, Minnesota.

PubMed DOI

Abstract

PURPOSE: Neuroendocrine neoplasms (NENs) are increasingly recognized to have a hereditary predilection, yet the prevalence and clinical relevance of pathogenic germline variants (PGVs) in unselected NEN patients remain poorly defined. This prospective, multicenter study aimed to evaluate the prevalence and clinical utility of PGVs through universal multi-gene panel testing in a diverse cohort of N…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.